Lipogen attained a U.S. patent for its phospholipid formulation targeting symptoms of premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PMDD).
Lipogen (Haifa, Israel) announced last week it has attained a U.S. patent for its phospholipid formulation targeting symptoms of premenstrual syndrome (PMS) and premenstrual dysphoric disoreder (PMDD).
The new patent for Lipogen’s phospholipid formulation is approved for “compositions and methods for alleviating symptoms associated with premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PMDD).”
The patent comes after a recent study revealed a previously unrecognized PMS/PMDD benefit of Lipogen’s PS Plus ingredient.
“When the benefits of phospholipids on PMS and PMDD came to light through Lipogen’s research, we immediately explored its potential,” explains David Rutenberg, CEO, Lipogen. “Realizing the significance of this discovery, it encouraged us to further explore a product line for women’s health utilizing Lipogen’s proprietary phospholipid ingredients.”
The PMS/PMDD potential of Lipogen’s phospholipids first came to a light in a 2000-person study of Lipogen’s PS Plus ingredient for brain health and stress management. Out of 220 women under the age of 40 who consumed PS Plus regularly, 23 women (10.45%) reported relief of premenstrual syndromes, sleeping better, fewer mood swings, fewer hot flashes, and reduced stress.
“Based on these strong results, we improved the formulation and applied for a patent in the U.S. market,” says Rutenberg. He adds that Lipogen has also begun a double-blind, randomized, placebo-controlled clinical trial in Germany to learn more about the ways Lipogen’s formulation may help alleviate symptoms of PMS and PMDD.
Nutritional Outlook Magazine